FDA Approval Alert: The Need-to-Know | Trastuzumab Deruxtecan in HER2-Low/Ultralow Breast Cancer

In January 2025, the FDA approved trastuzumab deruxtecan for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have previously been treated with at least 1 type of endocrine therapy in the metastatic setting.

Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
T-DXd Benefit May Extend to Earlier Settings and HER2-Low Breast Cancers
Video
Jan 28, 2025 3:00 PM
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer
FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer
Article
Jan 27, 2025 11:26 PM
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.